Early Monitoring of cfDNA in Lung Cancer: What Can We Learn from the ALK+ NSCLC case?

Time: 9:30 am
day: Day Two


• Decreased cfDNA dVAF at 6 weeks was associated with response

• Deeper decreases in cfDNA dVAF at 6 weeks were associated with more prolonged PFS and OS

• Early cfDNA dynamics may predict lorlatinib efficacy in ALK-positive metastatic NSCLC